$ZFGN shares dropped 35 percent to $3.00 after the company disclosed that it has suspended IND Filing plans for Zgn-1258 based on non clinical finding in long-term toxicology. The company also reported Chief Medical Officer Dennis Kim resigned. A replacement was not mentioned. The company also reported a narrower-than-expected Q4 loss.